CompanyBioNTech SE
Germany
Biontech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and s...
Private/Public:
public
Phone: +49 6131 9084-0
Fax:+49 6131 9084-2121
Email:[email protected]
Website:http://biontech.de/
Address:An der Goldgrube 12, 55131 Mainz, Germany
2008
Since
1
Country
0
Top Service Category
0
Sub-Service Category
Top Services
Germany
- (23.Jun.2022) BioNTech Receives Priority Medicines (PRIME) Designation From EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
- (23.Jun.2022) BioNTech Starts Construction of First MRNA Vaccine Manufacturing Facility in Africa
- (22.Jun.2022) Sanford to Offer COVID-19 Vaccine to Kids 6 Months & Older
- (17.Jun.2022) Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months Through 4 Years of Age
- (15.Jun.2022) Information on Dividend Payment and Tax Deduction
- (09.Jun.2022) BioNTech to Provide an Update on Manufacturing and Development Plans of MRNA Vaccines in Africa
- (05.Jun.2022) Positive Phase 1 Data from MRNA-Based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer Presented at ASCO
- (24.May.2022) Pfizer/BioNTech COVID-19 Vaccine Produces Strong Immune Response in Children
- (23.May.2022) Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
- (17.May.2022) Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
- (16.May.2022) Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission
- (10.May.2022) BioNTech Announces First Quarter Financial Results and Corporate Update
- (26.Apr.2022) Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age
- (14.Apr.2022) Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
- (11.Apr.2022) BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
- (11.Apr.2022) BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
- (08.Apr.2022) BioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health
- (31.Mar.2022) BioNTech Announces American Depositary Shares Repurchase Program
- (30.Mar.2022) BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
- (29.Mar.2022) Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
- (16.Mar.2022) Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of Their COVID-19 Vaccine for Older Adults
- (14.Mar.2022) Pfizer Highlights Need for Fourth Dose of COVID-19 Vaccine to FDA
- (11.Mar.2022) Study Shows Pfizer Vaccine Is Moderately Effective Against Omicron for Children 5-15
- (08.Mar.2022) BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo (Cemiplimab) Combination in NSCLC
- (01.Mar.2022) A Joint Research Between Kobe University School of Medicine and Our R &D Department "Study on the Safety and Immunogenicity of MRNA Vaccination in Japanese Patients After Allogeneic Stem Cell Transplantation" Was Published in "Vaccines" as a Co-Authored Paper
- (24.Feb.2022) Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 Through 17 Years of Age in the European Union
- (22.Feb.2022) BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
- (17.Feb.2022) DaVita Clinical Research Study Finds Efficacy of Common COVID-19 Vaccines at Parity for Kidney Patients
- (16.Feb.2022) BioNTech Portable Vaccine Factories – A Solution in Search of a Problem, Says AHF
- (16.Feb.2022) BioNTech Introduces First Modular MRNA Manufacturing Facility to Promote Scalable Vaccine Production in Africa
- (11.Feb.2022) Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
- (08.Feb.2022) AGC Biologics Supports Omicron-Based Vaccine Candidate Manufacturing With Starting Material
- (01.Feb.2022) Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
- (25.Jan.2022) Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
- (24.Jan.2022) Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-Induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant
- (14.Jan.2022) BioNTech and InstaDeep Collaboration Develops SARS-CoV-2 Early Warning System
- (12.Jan.2022) Positive Top-Line Results of Pfizer's Phase 3 Study Exploring Coadministration of PREVNAR 20 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
- (12.Jan.2022) Pfizer CEO Announces Plans to Launch Omicron-Specific COVID-19 Vaccine
- (10.Jan.2022) BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-Specific Precision Immunotherapies
- (10.Jan.2022) Pfizer Plans to Start Human Studies of Its Omicron-Specific COVID-19 Vaccine Before the End of January
- (05.Jan.2022) Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
- (03.Jan.2022) Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
- (23.Dec.2021) Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY in Adolescents 12 Through 15 Years of Age to EMA
- (20.Dec.2021) Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY to Help Meet Continued Need for Vaccine Supply
- (17.Dec.2021) Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY in Adolescents 12 Through 15 Years of Age
- (17.Dec.2021) Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine
- (09.Dec.2021) Pfizer/BioNTech Promote Booster Against Omicron
- (09.Dec.2021) Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- And 17-Year-Olds
- (08.Dec.2021) Pfizer and BioNTech Provide Update on Omicron Variant
- (06.Dec.2021) Phagomed Acquired by BioNTech SE
- (05.Dec.2021) Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-Cell Responses
- (29.Nov.2021) DaVita Clinical Research Study Indicates Effectiveness of mRNA COVID-19 Vaccines in Dialysis Patients
- (25.Nov.2021) Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty in Children 5 to <12 Years of Age in the European Union
- (22.Nov.2021) Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
- (19.Nov.2021) Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
- (19.Nov.2021) Health Canada Authorizes Use of Comirnaty (The Pfizer-BioNTech COVID-19 Vaccine) in Children 5 to 11 Years of Age
- (19.Nov.2021) BioNTech Receives FDA Fast Track Designation for Its FixVac Candidate BNT111 in Advanced Melanoma
- (17.Nov.2021) Kids Mobile Medical Clinic/Ronald McDonald Care Mobile Takes COVID-19 Vaccines on the Road for Children in Washington, D.C.'s Most Underserved Neighborhoods
- (11.Nov.2021) Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First MRNA COVID-19 Vaccines in Ghana
- (09.Nov.2021) Pfizer Internally Reviewing Covid-19 Vaccine Clinical Trial Misconduct Allegations
- (09.Nov.2021) Health Canada Authorizes the Use of the Pfizer-BioNTech Comirnaty COVID-19 Vaccine as a Booster Shot
- (09.Nov.2021) BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
- (09.Nov.2021) Elicera Therapeutics Enters Agreement with BioNTech for Contract Manufacturing of Viral Vectors for CAR T-Cell Therapy
- (03.Nov.2021) Walgreens to Provide Pfizer COVID-19 Vaccines to Children Ages 5 to 11 at Select Stores Nationwide Beginning Saturday
- (29.Oct.2021) Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
- (28.Oct.2021) Blue Cross Blue Shield of Massachusetts to Cover Pfizer/BioNTech COVID-19 Vaccines for Kids 5-11 at No Cost to Members
- (26.Oct.2021) Announcement at kENUP Roundtable: BioNTech Plans mRNA Facility in Africa in Mid-2022
- (26.Oct.2021) FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
- (21.Oct.2021) Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
- (21.Oct.2021) Novartis Signs New Initial Agreement With Biontech To Support Fill And Finish Of The mRNA Pfizer-BioNTech COVID-19 Vaccine
- (18.Oct.2021) EMA Starts Evaluating Use of COVID-19 Vaccine Comirnaty in Children Aged 5 to 11
- (15.Oct.2021) Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY
- (08.Oct.2021) Department of Disease Control Appoints Zuellig Pharma to Handle 20 Million Doses Pfizer-biontech Covid-19 Vaccines in Thailand
- (04.Oct.2021) Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
- (01.Oct.2021) BioNTech Expands Clinical Oncology Portfolio With First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
- (28.Sep.2021) Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
- (28.Sep.2021) Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
- (27.Sep.2021) Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
- (23.Sep.2021) Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
- (22.Sep.2021) Pfizer and BioNTech Expand Collaboration With U.S. To Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
- (20.Sep.2021) Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
- (20.Sep.2021) Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty, Spikevax and Vaxzevria for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively
- (17.Sep.2021) FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
- (16.Sep.2021) Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full Health Canada Approval for Individuals 12 Years and Older
- (14.Sep.2021) City of Hope Trial Is First to Test an Investigational COVID-19 Vaccine in Immunocompromised Bone Marrow Transplant and Cellular Therapy Patients With Blood Cancers
- (27.Aug.2021) Proof of Vaccination Must Now Include Proof of Booster
- (26.Aug.2021) Pfizer and BioNTech Announce Collaboration With Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
- (25.Aug.2021) FDA Approves COMIRNATY, the First COVID-19 Vaccine Approved by the Agency and the First COVID-19 Vaccine Brand Name Approved in the U.S
- (25.Aug.2021) Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY in Individuals 16 and Older
- (24.Aug.2021) FDA Approves First COVID-19 Vaccine Which Can Be Distributed by Global WholeHealth Partners Corp as US Anticipates Considerable Uptick in Vaccination Rates, as Stated in 8K Filing 06/15/21
- (23.Aug.2021) Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full U.S. FDA Approval for Individuals 16 Years and Older
- (18.Aug.2021) Pfizer/BioNTech Submit Data for COVID-19 Booster Shots
- (16.Aug.2021) Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
- (12.Aug.2021) Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
- (11.Aug.2021) BioNTech to Use COVID Vaccine Profits to “Expand and Accelerate” Pipeline
- (11.Aug.2021) BioNTech Says Booster Doses May Be More Effective Than a Modified COVID-19 Vaccine
- (09.Aug.2021) BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
- (04.Aug.2021) BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
- (03.Aug.2021) New European Supply Deals Show Pfizer and Moderna Have Increased COVID-19 Vaccine Prices
- (30.Jul.2021) Zuellig Pharma Thailand Collaborates with the Department of Disease Control (Ddc) to Provide Nationwide Distribution Services of 1.5Million Doses of Pfizer-biontech Covid-19 Mrna Vaccines
- (26.Jul.2021) Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria Vaccine, and the Set-Up of Manufacturing Infrastructures in Africa
- (26.Jul.2021) Mixing AZ and Pfizer COVID-19 Vaccines Increases Antibody Levels
- (26.Jul.2021) BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent
- (23.Jul.2021) Pfizer and BioNTech to Provide U.S. Government With an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
- (22.Jul.2021) Statement on BioNTech's Support for Flood-Hit Areas in North Rhine-Westphalia and Rhineland-Palatinate
- (21.Jul.2021) Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
- (19.Jul.2021) BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
- (16.Jul.2021) U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine
- (12.Jul.2021) 10 Million Doses of MRNA-Based COVID-19 Vaccine to Be Supplied to Taiwan Region
- (09.Jul.2021) Pfizer, BioNTech Eye US Approval for COVID-19 Booster Dose